Objective: To evaluate the effect of apolipoprotein E 4 (APOE 4) on striatal vesicular monoamine transporter-2 (VMAT2) density in Parkinson’s disease (PD).To evaluate the effect of apolipoprotein E 4 (APOE 4) on striatal vesicular monoamine transporter-2 (VMAT2) density in Parkinson’s disease (PD).

Background: VMAT2 is considered to be an objective biomarker of presynaptic dopaminergic nerve terminals in the striatum of PD patients. APOE 4 is associated with the risk of early PD, and whether it has a direct effect on dopaminergic system is unclear.

Method: Longitudinal data were obtained from 19 PD patients who were classified as APOE 4 carriers (n = 7) and non-carriers (n = 12) in the Parkinson’s Progression Marker Initiative. The availability of VMAT2 in the caudate, anterior and posterior putamen was assesed using ¹⁸F-AV-133 PET at baseline and the 1- and 3-year follow-up. ¹⁸F-AV-133 striatal binding ratio (SBR) was calculated as (target region/reference region)-1 using the occipital lobe as the reference region. Independent-samples t-test and linear mixed model were used to assess the effect of APOE 4.

Results: At beasline, APOE 4 carriers showed lower ¹⁸F-AV-133 SBR than non-carriers in the caudate, anterior and posterior putamen, but not statistically significant (p > 0.05). At 1- and 3-year follow-up, APOE 4 carriers exhibited greater magnitude of longitudinal changes in straital ¹⁸F-AV-133 SBR than non-carriers, but again not statistically significant.

Conclusion: APOE 4 has no significant effect on dopaminergic system in patients with PD.

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-effect-of-apoe-%ce%b54-on-striatal-vesicular-monoamine-transporter-2-density-in-parkinsons-disease/